We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+14.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$736M
AUM Growth
+$94.9M
Cap. Flow
+$68.2M
Cap. Flow %
9.27%
Top 10 Hldgs %
43.9%
Holding
93
New
21
Increased
19
Reduced
26
Closed
17

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$30.8M
2
CRL icon
Charles River Laboratories
CRL
+$27.9M
3
LLY icon
Eli Lilly
LLY
+$25.6M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$20.8M
5
NVST icon
Envista
NVST
+$18.2M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$14.8M
2
ANAB icon
AnaptysBio
ANAB
+$13.6M
3
UTHR icon
United Therapeutics
UTHR
+$13.6M
4
ANGO icon
AngioDynamics
ANGO
+$13M
5
APEN
Apollo Endosurgery, Inc.
APEN
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.93%
2 Consumer Staples 4.27%
3 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGO
51
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$3.21M 0.44%
+213,000
New +$3.45M
KYNB
52
Kyntra Bio
KYNB
$28.9M
$3.04M 0.41%
9,361
-2,728
-23% -$879K
LYRA
53
DELISTED
LYRA THERAPEUTICS INC
LYRA
$2.97M 0.4%
11,848
– –
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$5.89B
$2.85M 0.39%
135,618
-60,400
-31% -$1.45M
OSUR icon
55
OraSure Technologies
OSUR
$274M
$2.14M 0.29%
+565,000
New +$2.04M
INMD icon
56
InMode
INMD
$874M
$1.96M 0.27%
67,449
-120,000
-64% -$3.72M
DXCM icon
57
DexCom
DXCM
$31.6B
$1.92M 0.26%
23,836
-23,400
-50% -$1.98M
ETNB
58
DELISTED
89bio
ETNB
$1.91M 0.26%
+330,000
New +$1.45M
EIGR
59
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.65M 0.22%
7,300
-20,900
-74% -$5.14M
ANAB icon
60
AnaptysBio
ANAB
$1.64B
$1.63M 0.22%
64,027
-579,548
-90% -$13.6M
KDNY
61
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.53M 0.21%
78,000
-10,000
-11% -$201K
FATE icon
62
Fate Therapeutics
FATE
$289M
$1.51M 0.2%
67,300
-127,100
-65% -$3.67M
CRSP icon
63
CRISPR Therapeutics
CRSP
$5.17B
$1.44M 0.2%
22,000
– –
NVO
64
Novo Nordisk
NVO
$209B
$1.41M 0.19%
+28,200
New +$1.51M
VSTM icon
65
Verastem
VSTM
$538M
$1.4M 0.19%
137,042
– –
XLO icon
66
Xilio Therapeutics
XLO
$60.2M
$1.32M 0.18%
32,404
– –
YMAB
67
DELISTED
Y-mAbs Therapeutics
YMAB
$1.26M 0.17%
87,182
-49,000
-36% -$811K
PEPG icon
68
PepGen
PEPG
$170M
$1.18M 0.16%
130,000
-45,000
-26% -$442K
APLS
69
DELISTED
Apellis Pharmaceuticals
APLS
$915K 0.12%
+13,400
New +$793K
IOBT
70
DELISTED
IO Biotech
IOBT
$781K 0.11%
288,119
-367,285
-56% -$1.36M
IMUX icon
71
Immunic
IMUX
$205M
$758K 0.1%
24,000
– –
DALS
72
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$487K 0.07%
50,000
– –
PLRX icon
73
Pliant Therapeutics
PLRX
$64.4M
$443K 0.06%
21,200
-468,800
-96% -$8.97M
RCKT icon
74
Rocket Pharmaceuticals
RCKT
$382M
$404K 0.05%
25,300
-292,800
-92% -$4.57M
VRDN icon
75
Viridian Therapeutics
VRDN
$2.57B
$400K 0.05%
19,518
-821,500
-98% -$14.8M
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Soleus Capital Management held 93 positions worth $736M, up 15% from $641M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Soleus Capital Management deployed $68.2M of net new capital in Q3 2022, opening 21 new positions and adding to 19 existing holdings. Its largest new stake was Illumina: 155,845 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $14.8M trimmed.

  • Soleus Capital Management's largest Q3 2022 buy was Illumina: 155,845 shares worth $28.9M.
  • Soleus Capital Management added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $20.8M increase.
  • Soleus Capital Management's biggest Q3 2022 reduction was Viridian Therapeutics, cutting an estimated $14.8M.
  • Soleus Capital Management fully exited AngioDynamics in Q3 2022, selling an estimated $13M.
  • Soleus Capital Management's ten largest holdings make up 44% of its $736M portfolio in Q3 2022.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q3 2022.
  • Soleus Capital Management's portfolio value rose 15% quarter-over-quarter to $736M.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.